TY - JOUR T1 - Pharmacogenomic and drug interaction risk associations with hospital length of stay among Medicare Advantage members with COVID-19 JF - medRxiv DO - 10.1101/2021.05.06.21256769 SP - 2021.05.06.21256769 AU - Kristine Ashcraft AU - Chad Moretz AU - Chantelle Schenning AU - Susan Rojahn AU - Kae Vines Tanudtanud AU - Gwyn Omar Magoncia AU - Justine Reyes AU - Bernardo Marquez AU - Yinglong Guo AU - Elif Tokar Erdemir AU - Taryn O. Hall Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/13/2021.05.06.21256769.abstract N2 - Importance COVID-19 has severely impacted older populations and strained healthcare resources, with many patients requiring long periods of hospitalization. Reducing the hospital length of stay (LOS) reduces patient and hospital burden. Given that adverse drug reactions are known to prolong LOS, unmanaged pharmacogenomic risk and drug interactions among COVID-19 patients may be a risk factor for longer hospital stays.Objective The objective of this study was to determine if pharmacogenomic and drug interaction risks were associated with longer lengths of stay among high-risk patients hospitalized with COVID-19.Design Retrospective cohort study of medical and pharmacy claimsSetting Administrative database from a large U.S. health insurance companyParticipants Medicare Advantage members with a first COVID-19 hospitalization between January 2020 and June 2020, who did not die during the stay.Exposures (1) Pharmacogenetic interaction probability (PIP) of ≤25% (low), 26%–50% (moderate), or >50% (high), which indicate the likelihood that one or more clinically actionable gene-drug or gene-drug-drug interactions would be identified with testing; (2) drug-drug interaction (DDI) severity of minimal, minor, moderate, major, or contraindicated, which indicate the severity of an interaction between two or more active medications.Main Outcomes and Measures The primary outcome was hospital length of stay. Results were stratified by hierarchical condition categories (HCC) counts and chronic conditions.Results A total of 6,025 patients hospitalized with COVID-19 were included in the study. Patients with moderate or high PIP were hospitalized for 9% (CI: 4%–15%; p < 0.001) and 16% longer (CI: 8%–24%; p < 0.001), respectively, compared to those with low PIP, whereas RAF score was not associated with LOS. High PIP was significantly associated with 12%–22% longer lengths of stay compared to low PIP in patients with hypertension, hyperlipidemia, diabetes, or COPD. Finally, among patients with 2 or 3 HCCs, a 10% longer length of stay was observed among patients with moderate or more severe DDI compared to minimal or minor DDI.Conclusions and Relevance Proactively mitigating pharmacogenomic risk has the potential to reduce length of stay in patients hospitalized with COVID-19 especially those with COPD, diabetes, hyperlipidemia, and hypertension.Question What is the impact of unmanaged pharmacogenomic risk among patients hospitalized with COVID-19?Findings Among 6,025 patients hospitalized with COVID-19, those with greater unmanaged pharmacogenomic risk for adverse drug reactions had longer hospital stays than those with lower risk, both within the entire cohort and within groups matched by number and type of chronic conditions.Meaning Preemptive pharmacogenomic testing may shorten hospital stay by reducing adverse drug reactions among seriously ill patients and more broadly improve patient risk classification, care utilization predictions, and health system performance.Competing Interest StatementAuthors K. Ashcraft, C. Moretz, C. Schenning, and S. Rojahn are employees of genetic testing company Invitae. Authors G.O. Magoncia, J. Reyes, B. Marquez, Y. Guo, E. T. Erdemir, and T. O. Hall are employees of UHG. Author K.V. Tanudtanud is a former employee of UHG.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The de-identified data used in this study were granted a waiver of authorization by the institutional review board of the UnitedHealth Group Office of Human Research Affairs.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analyzed in this study was obtained from UnitedHealth Group Clinical Discovery Portal. The data are proprietary and are not available for public use but, under certain conditions, may be made available to editors and their approved auditors under a data-use agreement to confirm the findings of the current study. Further inquiries can be directed to Lauren Mihajlov.COVID-19Coronavirus-induced disease 2019CPICClinical Pharmacogenetics Implementation ConsortiumDDIDrug-drug interactionFDAU.S. Food and Drug AdministrationHCChierarchical conditions categoriesLOSLength of stayPIPPharmacogenetic interaction probabilityRAFRisk adjustment factorSNPSpecial needs plan ER -